Survey on antimicrobial resistance patterns in Vibrio vulnificus and Vibrio cholerae non-O1/non-O139 in Germany reveals carbapenemase-producing Vibrio cholerae in coastal waters by Nadja Bier et al.
ORIGINAL RESEARCH
published: 28 October 2015
doi: 10.3389/fmicb.2015.01179
Frontiers in Microbiology | www.frontiersin.org 1 October 2015 | Volume 6 | Article 1179
Edited by:
Learn-Han Lee,
Monash University Malaysia, Malaysia
Reviewed by:
Weili Liang,
Chinese Center for Disease Control
and Prevention, China
Adrian Canizalez-Roman,
Autonomous University of Sinaloa,
Mexico
Vengadesh Letchumanan,
University of Malaya, Malaysia
*Correspondence:
Eckhard Strauch
eckhard.strauch@bfr.bund.de
Specialty section:
This article was submitted to
Food Microbiology,
a section of the journal
Frontiers in Microbiology
Received: 05 August 2015
Accepted: 12 October 2015
Published: 28 October 2015
Citation:
Bier N, Schwartz K, Guerra B and
Strauch E (2015) Survey on
antimicrobial resistance patterns in
Vibrio vulnificus and Vibrio cholerae
non-O1/non-O139 in Germany reveals
carbapenemase-producing Vibrio
cholerae in coastal waters.
Front. Microbiol. 6:1179.
doi: 10.3389/fmicb.2015.01179
Survey on antimicrobial resistance
patterns in Vibrio vulnificus and
Vibrio cholerae non-O1/non-O139 in
Germany reveals
carbapenemase-producing Vibrio
cholerae in coastal waters
Nadja Bier, Keike Schwartz, Beatriz Guerra and Eckhard Strauch*
Department of Biological Safety, Federal Institute for Risk Assessment, Berlin, Germany
An increase in the occurrence of potentially pathogenic Vibrio species is expected for
waters in Northern Europe as a consequence of global warming. In this context, a
higher incidence of Vibrio infections is predicted for the future and forecasts suggest
that people visiting and living at the Baltic Sea are at particular risk. This study
aimed to investigate antimicrobial resistance patterns among Vibrio vulnificus and Vibrio
cholerae non-O1/non-O139 isolates that could pose a public health risk. Antimicrobial
susceptibility of 141 V. vulnificus and 184 V. cholerae non-O1/non-O139 strains isolated
from German coastal waters (Baltic Sea and North Sea) as well as from patients and
retail seafood was assessed by broth microdilution and disk diffusion. Both species were
susceptible to most of the agents tested (12 subclasses) and no multidrug-resistance
was observed. Among V. vulnificus isolates, non-susceptibility was exclusively found
toward aminoglycosides. In case of V. cholerae, a noticeable proportion of strains
was non-susceptible to aminopenicillins and aminoglycosides. In addition, resistance
toward carbapenems, quinolones, and folate pathway inhibitors was sporadically
observed. Biochemical testing indicated the production of carbapenemases with unusual
substrate specificity in four environmental V. cholerae strains. Most antimicrobial agents
recommended for treatment of V. vulnificus and V. cholerae non-O1/non-O139 infections
were found to be effective in vitro. However, the occurrence of putative carbapenemase
producing V. cholerae in German coastal waters is of concern and highlights the need for
systematic monitoring of antimicrobial susceptibility in potentially pathogenic Vibrio spp.
in Europe.
Keywords: antimicrobial resistance pattern, Baltic Sea, North Sea, carbapenemase, disk diffusion, broth
microdilution
INTRODUCTION
The familyVibrionaceaewithin the class of Gammaproteobacteria comprises eight genera of Gram-
negative, facultative anaerobic, straight, or curved rods that are mostly oxidase-positive, halophilic,
and motile (Farmer and Janda, 2004). Members of this family are ubiquitously distributed in
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aquatic ecosystems worldwide. They can be found as free-living
bacteria and as commensals of aquatic organisms and play an
important role in nutrient cycling of natural aquatic habitats.
Due to their metabolic diversity and their adaptive abilities to
changing environmental conditions, a seasonal, and geographical
variability of total Vibrio populations is observed in response
to climatic influences and seawater circulations (Mansergh and
Zehr, 2014).
Among the Vibrionaceae, a number of important human
pathogenic bacteria have been identified that can cause
gastrointestinal infections, wound infections or septicemia.
Vibrio cholerae, Vibrio vulnificus, and Vibrio parahaemolyticus
are considered as the most clinically relevant human pathogens
within the genus Vibrio (Daniels and Shafaie, 2000). The latter
species is widely disseminated in estuarine, marine, and coastal
so surroundings and the leading cause of human intestinal
infections after consumption of raw and undercooked seafood
(Letchumanan et al., 2014). V. cholerae and V. vulnificus are also
part of the microbial community in coastal or estuarine aquatic
ecosystems with moderate salinities (Thompson and Polz, 2006).
V. cholerae is a well-known human pathogen consisting of
more than 200 serogroups (Kaper et al., 1995; Lutz et al., 2013).
Toxigenic V. cholerae of the O1 or O139 serogroup are the
causative agents of cholera, an endemic disease in many Asian
and African countries with symptoms of severe watery diarrhea,
vomiting, and dehydration. All other serogroups designated asV.
cholerae non-O1/non-O139 have also been linked to sporadically
occurring human infections ranging from extraintestinal wound
or ear infections (Huhulescu et al., 2007) to relatively mild or
sometimes severe gastroenteritis (Tobin-D’Angelo et al., 2008),
whereby smaller diarrheal outbreaks were also reported (Luo
et al., 2013). Additionally, rarely occurring bacteremia has been
described with mortality rates up to 61.5% (Petsaris et al., 2010).
Since 2000, around 40 cases of V. cholerae non-O1/non-O139
infections in the United States have been reported to the CDC
annually1. V. cholerae infections contracted in Germany were
mainly ear or wound infections caused by non-toxigenic non-
O1/non-O139 strains that were acquired through contact to
seawater (Huehn et al., 2014). Due to the rare occurrence of
V. cholerae non-O1/non-O139 infections, there are no official
recommendations on antibiotic therapy (Petsaris et al., 2010).
However, in case of bacteremia an early administration of
antibiotic therapy can prevent a fatal outcome. Several case
studies on V. cholerae non-O1/non-O139 bacteremia and wound
infection exist, where fluoroquinolones and third-generation
cephalosporins have been used (Huhulescu et al., 2007; Petsaris
et al., 2010). But also treatment with ampicillin or last-line
carbapenems has been described (Feghali and Adib, 2011; Lu
et al., 2014).
V. vulnificus is known as a highly virulent pathogen. Although
infections occur only sporadically, they can rapidly progress to
septicemia, especially in persons with predisposing risk factors
(e.g., immunocompromising conditions or chronic liver diseases
resulting in elevated serum iron levels; Oliver, 2006). Foodborne
infections can either result in a relatively mild gastroenteritis
1http://www.cdc.gov/cholera/non-01-0139-infections.html
or in primary septicemia with mortality rates of 61% (Shapiro
et al., 1998; Oliver, 2006). A second infection route for V.
vulnificus is through open wounds exposed to seawater. Due to
the high multiplication rate of the pathogen, wound infections
may quickly progress to necrotizing fasciitis, which often makes
surgical debridement or amputation necessary (Daniels and
Shafaie, 2000). Delayed treatment promotes progression to
secondary septicemia with mortality rates about seventeen per
cent (Shapiro et al., 1998; Daniels and Shafaie, 2000). Surgical
interventions should be considered early to prevent a fatal
outcome as poor blood perfusion in necrotic tissue can impede
the achievement of effective concentrations of antimicrobial
agents (Chen et al., 2012). However, to avoid septicemia and
a further distribution of the pathogen additional antibiotic
therapy is indispensable and should be administered as early as
possible. Due to the fast progression of V. vulnificus infections,
the presence of antimicrobial resistance preventing an effective
therapy can be fatal for the patient. A combination of a
tetracycline with a third-generation cephalosporin or single-
agent therapy with fluoroquinolones is recommended by the
CDC2, while trimethoprim-sulfamethoxazole in combination
with an aminoglycoside is proposed for the treatment of pregnant
women and children.
In the U.S., 95% of all seafood-related deaths can be attributed
to V. vulnificus, whereas infections in Germany were almost
exclusively wound infections occurring after contact to seawater
(Oliver, 2006; Huehn et al., 2014). So far, Vibrio infections in
Germany occur only sporadically but incidences peaked after
extreme heatwaves (Huehn et al., 2014). Due to impacts of
climate change, a rise in the occurrence of V. vulnificus and V.
cholerae is predicted for European waters (Baker-Austin et al.,
2012). Changing demography is expected to further contribute to
higher incidences of Vibrio infections (Baker-Austin et al., 2012).
In view of these forecasts and the potential severity of infections,
an investigation on antimicrobial susceptibility of Vibrio spp.
is demanded to provide guidance for medical intervention, but
also for epidemiological purposes. For this reason, our study
aimed to assess antimicrobial resistance prevalence among V.
vulnificus and V. cholerae non-O1/non-O139 posing a public
health risk for the population. Environmental isolates were
obtained from German coastal and estuarine waters of the open
North Sea and the intracontinental Baltic Sea. In addition, we
also included isolates from clinical sources and retail seafood
for comparison and to give a more comprehensive overview
of antimicrobial resistance patterns of these two species in
Germany. To our knowledge, this is the first study examining
antimicrobial susceptibility of V. vulnificus and V. cholerae non-
O1/non-O139 in Northern Europe on a large scale.
MATERIALS AND METHODS
Bacterial Strains
The strains used in this study are summarized in Table 1 and
listed in detail in Supplementary Tables S1, S2. Antimicrobial
susceptibilities were determined for a total of 325 bacterial
2 http://emergency.cdc.gov/disasters/vibriovulnificus.asp
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TABLE 1 | Origin and source of V. cholerae non-O1/non-O139 (n = 184) and V. vulnificus (n = 141) strains included in the study.
Origin Geographical origin Source Source code No. of strains
V. cholerae
Environmental (E) (2009–2014; n = 131) Baltic Sea (BS) (n = 79) Seawater (sw) E-BS-sw 54
Sediment (sd) E-BS-sd 4
Seawater/sediment (sw/sd) E-BS-sw/sd 21
North Sea (NS) (n = 52) Bivalve mollusks (bm) E-NS-bm 26
Seawater (sw) E-NS-sw 12
Seawater/sediment (sw/sd) E-NS-sw/sd 14
Clinical (C) (1995–2012; n = 18) Travel-associated (ta) (n = 7) Extraintestinal (ext) C-ta-ext 1
Intestinal (int) C-ta-int 6
Germany/Austria (G/A) (n = 11) Extraintestinal (ext) C-G/A-ext 9
Intestinal (int) C-G/A-int 2
Retail (R) (2008–2014; n = 35) Germany (G) (n = 35) Bivalve mollusks (bm) R-G-bm 2
Crustacean (cr) R-G-cr 26
Fish (fi) R-G-fi 7
V. vulnificus
Environmental (E) (2004–2012; n = 122) Baltic Sea (BS) (n = 70) Seawater (sw) E-BS-sw 46
Sediment (sd) E-BS-sd 24
North Sea (NS) (n = 52) Seawater (sw) E-NS-sw 29
Sediment (sd) E-NS-sd 21
Bivalve mollusks (bm) E-NS-bm 2
Clinical (C) (1994–2011; n = 19) Denmark (D) Extraintestinal (ext) C-D-ext 14
Germany (G) Extraintestinal (ext) C-G-ext 5
strains, including 141 isolates of V. vulnificus (19 clinical, 122
environmental) and 184 isolates of V. cholerae non-O1/non-
O139 (18 clinical, 131 environmental, 35 retail). The majority
of environmental strains were isolated by health authorities
during the German research programs KLIWAS3 and VibrioNet4
between 2004 and 2014. Water and sediment samples were
mostly collected at bathing sites along the Baltic Sea and
North Sea coastline as well as within the estuaries of the rivers
Ems and Weser (Böer et al., 2012). Environmental isolates
from bivalve mollusks were obtained from coastal areas of the
North Sea. Isolates from retail samples were collected by health
authorities of Germany and sent to the National Reference
Laboratory for Monitoring Bacteriological Contamination of
Bivalve Mollusks of the Federal Institute for Risk Assessment
(BfR), Germany. Clinical V. vulnificus and V. cholerae non-
O1/non-O139 isolates were characterized in previous studies
(Bier et al., 2013; Schirmeister et al., 2014).
DNA Extraction
DNA extraction was performed with two methods that are
equally applicable for Vibrio species. Genomic DNA of V.
vulnificus isolates was extracted from 1ml of an overnight culture
using the RTP Bacteria DNA Kit according to the manufacturer’s
protocol (STRATEC Biomedical AG, Birkenfeld, Germany).
Genomic DNA of V. cholerae strains was extracted using a
boiling method: 1.5ml of an overnight culture were centrifuged
3http://www.kliwas.de/KLIWAS/EN/03_ResearchTasks/03_vh3/04_304/304_
node.html
4http://www.vibrionet.de/
at 14,000 g for 4min. The cell pellet was suspended in 300µl TE
buffer (10mM Tris-HCl, 0.5mM EDTA, pH 8), boiled for 10min
at 95◦C, and subsequently cooled on ice. After centrifugation
at 14,000 g for 2min, a 200µl aliquot of the supernatant was
transferred to a new sterile tube. DNA preparations were stored
at−20◦C.
Species Confirmation
Species confirmation of all V. vulnificus and V. cholerae strains
was carried out by species-specific toxR PCR amplification
as previously described (Bauer and Røervik, 2007) and
in parallel by MALDI-TOF MS analysis. MALDI-TOF MS
analysis was performed using a Microflex LT system mass
spectrometer (Bruker Daltonik, Bremen, Germany) following the
manufacturer’s settings. MALDI spectra were obtained by the
direct transfer method according to the manufacturer’s protocol
as previously described (Schirmeister et al., 2014).
Characterization of V. cholerae Isolates
V. cholerae isolates were characterized and subtyped viamultiplex
PCR targeting rfb sequences specific for O1 andO139 serogroups,
toxR, and ctxA. PCR amplification was performed in a final
volume of 25µl with 1x PCR buffer (3mM MgCl2), 0.2mM of
each deoxynucleoside triphosphate, 0.5µM of O1 rfb primers,
0.125µM of O139 rfb, toxR, and ctxA primers, 1.5 U DreamTaq
DNA polymerase (Thermo Fisher Scientific Biosciences GmbH,
St. Leon-Rot, Germany), and 2µl of genomic DNA. After an
initial denaturation step at 94◦C for 4min, the cycling conditions
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were the following: 30 cycles at 94◦C for 30 s, 59◦C for 30 s, 72◦C
for 30 s, followed by a final extension step at 72◦C for 5min.
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility to the following 13 antimicrobial
agents was determined by broth microdilution according
to the guidelines of the Clinical and Laboratory Standards
Institute (CLSI, 2012a) using custom-defined microtiter plates
(EUMVS2, Trek Diagnostic Systems, East Grinstead, United
Kingdom): ampicillin, ceftazidime, cefotaxime, chloramphenicol,
ciprofloxacin, colistin, florfenicol, gentamicin, kanamycin,
nalidixic acid, streptomycin, tetracycline, and trimethoprim.
Test ranges are shown in Supplementary Table S3. Additionally,
all isolates were tested for their susceptibility to amoxicillin-
clavulanic acid (20/10µg), cefepime (30µg), imipenem (10µg),
levofloxacin (5µg), meropenem (10µg), and sulfamethoxazole-
trimethoprim (23.75/1.25µg) by the disk diffusion method,
according to the guidelines of the CLSI using commercially
available disks (Oxoid GmbH, Wesel, Germany; CLSI, 2012b).
Strains showing non-susceptibility to imipenem (zone
diameter ≤ 19) were tested against an additional panel of
β-lactams by broth microdilution (imipenem, ertapenem,
cefepime, cefoxitin, temocillin; EUVSEC2, Trek Diagnostic
Systems) or disk diffusion (aztreonam, 30µg).
Following the guidelines of the CLSI, tests were performed
with Mueller-Hinton agar and cation-adjusted Mueller-Hinton
broth without supplementation of additional sodium chloride
(CLSI, 2010a). Escherichia coli ATCC 25922 was used for
quality assurance. Minimal inhibitory concentration (MIC)
values and inhibition zone diameters of all strains are listed
in Supplementary Tables S1, S2. Results were interpreted using
the criteria summarized in Supplementary Table S3. In general,
results were interpreted according to CLSI clinical breakpoints
specific for Vibrio spp. (CLSI, 2010a), which derived from
breakpoints for Enterobacteriaceae (CLSI, 2010b). In cases
where CLSI breakpoints for Vibrio spp. were obsolete or not
available, the latest CLSI breakpoints for Enterobacteriaceae were
used: document M100-S25 for aztreonam, cefepime, ertapenem,
gentamicin, kanamycin, imipenem, meropenem, nalidixic acid,
and trimethoprim (CLSI, 2015); document Vet01-S2 for
florfenicol (CLSI, 2013). Other interpretive criteria were used for
colistin (EUCAST clinical breakpoints for Enterobacteriaceae5
; EUCAST, 2015), temocillin (BSAC interpretive criteria for
systemic infections; Andrews, 2009), and streptomycin (based
on different studies of Vibrio spp. and E. coli; National Food
Institute, 2013; Shaw et al., 2014), as no CLSI breakpoints were
available.
Molecular Investigation of Resistance
Determinants
PCR amplification was conducted to detect specific antimicrobial
resistance determinants depending on the phenotype found.
Non-susceptible isolates were screened for genes mediating
resistance to streptomycin (aadA1, aadA2, and strA/B) and
β-lactams (blaPSE−1, blaOXA−1−like, blaTEM−1−like) that are
5http://www.eucast.org
widespread in Enterobacteriaceae and other Gram-negative
bacteria. Specifically imipenem-resistant strains (zone diameter
≤ 19) were tested for the presence of several carbapenemase and
AmpC β-lactamase encoding genes. Presence of class 1 integrons
was investigated by PCR amplification of the corresponding
integrase gene intI1 in all β-lactam and streptomycin non-
susceptible strains.
Standard PCR reactions were performed using a Mastercycler
EP gradient (Eppendorf, Hamburg, Germany) in a volume of
25µl with 1x PCR buffer (2mM MgCl2), 0.2mM of each
deoxynucleoside triphosphate (dNTP), 0.2µM of each primer,
1.5 U DreamTaq DNA polymerase, and 2µl of genomic DNA.
After an initial denaturation step at 94◦C for 4min, the cycling
conditions were the following: 30 cycles of denaturation at 94◦C
for 30 s, primer annealing for 30 s, and extension at 72 ◦C for
1min per kb, followed by a final extension step at 72◦C for
10min.
All primer pairs, target genes, corresponding annealing
temperatures, and amplicon sizes are listed in Supplementary
Table S4. Enterobacterial strains carrying class 1 integrons and
investigated resistance determinants (aadA1, aadA2, blaPSE−1,
blaOXA−1, blaTEM−1, blaNDM−1, blaIMP−1, blaVIM−2, blaKPC−3,
blaOXA−48, blaACC−1, blaCMY−1, blaCMY−2, blaDHA−1, blaACT−1,
blaFOX−1, strA, and strB), as well as one V. cholerae non-O1/non-
O139 isolate carrying a class 1 integron with the aadA1 gene were
used as positive controls. SusceptibleV. cholerae andV. vulnificus
strains were included as negative controls.
All streptomycin resistant V. cholerae (VN-3469, VN-5095,
VN-10191, and VN-10192) and V. vulnificus (VN-0098, VN-
0100, VN-0125, VN-0129) isolates were further examined for
mutations in the rpsL gene encoding ribosomal protein S12.
Streptomycin susceptible (V. cholerae: VN-0298, VN-2997, VN-
3955, VN-4226, andV. vulnificus: VN-0096, VN-0274, VN-3368)
and intermediate resistant strains (V. cholerae: VN-3944, VN-
4261, and V. vulnificus: VN-3418, VN-3981, VN-10121) were
included as controls. For specific amplification and sequencing
of the whole rpsL gene in V. cholerae and V. vulnificus, two
primer pairs Vc-rpsL-F/Vc-rpsL-R and Vv-rpsL-F/Vv-rpsL-R
were designed based on published genome sequences (V. cholerae
strains NIH41, N16961, O395, and V. vulnificus strains CMCP6,
YJ016, MO6-24/O). Purification of PCR products was performed
using the MSB R© Spin PCRapace Kit (STRATEC Biomedical AG,
Berlin, Germany). Sequencing was conducted on both strands
through sequencing service (Eurofins MWG GmbH, Ebersberg,
Germany). Electropherograms were assembled and trimmed
using SeqMan Pro (v12; DNASTAR Lasergene, Madison,
Wisconsin). Sequences were analyzed and compared to the
sequences of reference and control strains using Accelrys Gene
(v2.5, Accelrys Inc., San Diego, California).
Test for Carbapenemase Activity: Carba
NP Test II/Blue-Carba Test
Strains non-susceptible to imipenem (zone diameter ≤ 19) were
grown overnight at 37◦C on chromID™ CARBA (bioMérieux,
Nürtingen, Germany). Bacterial colonies were subsequently
tested for carbapenemase activity with the improved Carba NP
test II (Dortet et al., 2014) using 12 g/L imipenem/cilastatin
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(Zienam R©, MSD SHARP, and DOHME GMBH, Haar, Germany)
and two calibrated loops (10µl) as bacterial inoculum to
increase enzyme quantity. The Blue-CARBA test was performed
as described (Pires et al., 2013) and in addition analogously
to the Carba NP test II with two loops of bacterial colonies
in 200µl of the test solution in microcentrifuge tubes and
supplementation of tazobactam or EDTA to inhibit class A
or metallo-carbapenemases, respectively. Two E. coli strains
positive for NDM-1 and KPC-2, respectively, as well as a
KPC-3-positive Klebsiella pneumoniae strain served as positive
controls.
Statistical Analyses
Descriptive statistics were used to analyze resistance prevalence
to different antimicrobial agents (Table 2). Chi-square test for
independence was applied with 2 × 2 contingency tables to
test if observed differences displayed in Table 3 were statistically
significant (P-values ≤ 0.05). MIC50 and MIC90 were defined as
the concentration at which growth of 50 and 90% of the isolates
was inhibited, respectively.
RESULTS
Antimicrobial Susceptibility of Clinical and
Environmental V. vulnificus Isolates
Fifty-seven per cent of all examined V. vulnificus isolates
showed susceptibility to all antimicrobial agents tested (with
the exception of colistin). All 141 V. vulnificus isolates,
regardless of their origin were susceptible to quinolones,
fluoroquinolones, phenicols, tetracyclines, folate pathway
inhibitors, aminopenicillins with or without β-lactamase
inhibitors, carbapenems, and third- and fourth- generation
cephalosporins. The clinically relevant agents cefotaxime,
ceftazidime, and tetracycline were among the most effective
antimicrobial agents in vitro as they showed MIC90 values
identical to the lowest concentration tested (Table 4). Non-
susceptibility was exclusively observed toward aminoglycosides
with 40 and 3% of all strains showing intermediate resistance
(MIC 32 mg/L) and resistance (MIC 64 mg/L) to streptomycin,
respectively. One clinical isolate was intermediate resistant to
kanamycin (MIC 32 mg/L) while all strains were susceptible
to gentamicin. The percentage of non-susceptible strains with
respect to different origins is shown in Table 3. No significant
difference was observed between clinical (n = 19) and
environmental (n = 122) isolates, nor was there a significant
difference between isolates from the Baltic Sea and the North
Sea (p > 0.05, χ2). None of the examined gene determinants
encoding streptomycin resistance (aadA1, aadA2, strA/B), nor
class 1 integrons were detected in streptomycin non-susceptible
V. vulnificus isolates. Sequence analysis of the rpsL gene revealed
that all four streptomycin resistant V. vulnificus isolates (VN-
0098, VN-0100, VN-0125, VN-0129) as well as two susceptible
(VN-0274, VN-3368) and two intermediate resistant isolates
(VN-3918, VN-10121) carried one silent point mutation A-291-
T compared to the three reference strains (CMCP6, YJ016, and
MO6-24/O). An additional silent mutation C-351-T within the
rpsL gene was observed in strain VN-0100.
Antimicrobial Susceptibility of V. cholerae
non-O1/non-O139 Isolated from Clinical,
Environmental and Seafood Samples
All 184 isolates investigated in this study were confirmed to
be non-toxigenic V. cholerae non-O1/non-O139 isolates. The
TABLE 3 | Overall resistance occurrence in V. cholerae and V. vulnificus
isolates with respect to different origins.
Retail Clinical Environmental North Sea Baltic Sea
V. cholerae (n = 35) (n = 18) (n = 131) (n = 52) (n = 79)
Strains susceptible
to all antimicrobial
agents
27 (77%) 10 (56%) 86 (66%) 28 (54%) 58 (73%)
Non-susceptible
strains
8 (23%) 8 (44%) 45 (34%) 24(46%) 21 (27%)
V. vulnificus (n = 19) (n = 122) (n = 52) (n = 70)
Strains susceptible
to all antimicrobial
agents
8 (42%) 72 (59%) 28 (54%) 44 (63%)
Non-susceptible
strains
11 (58%) 50 (41 %) 24 (46 %) 26 (37 %)
TABLE 2 | Susceptibility vs. resistance occurrence (%) found among V. cholerae non-O1/non-O139 isolates from different originsa.
Antimicrobial agent Total (n = 184) Retail (n = 35) Clinical (n = 18) Environmental (n = 131) North Sea (n = 52) Baltic Sea (n = 79)
S I R S I R S I R S I R S I R S I R
Amoxicillin/clavulanic acid 98 2 0 100 0 0 100 0 0 97 3 0 94 6 0 99 1 0
Ampicillin 89 0 11 89 0 11 83 0 17 90 0 10 85 0 15 94 0 6
Imipenem 97 1 2 100 0 0 100 0 0 95 2 3 94 0 6 96 3 1
Meropenem 98 2 <1 100 0 0 100 0 0 97 2 1 94 4 2 99 1 0
Nalidixic acid 99 0 1 100 0 0 89 0 11 100 0 0 100 0 0 100 0 0
Streptomycin 78 20 2 86 11 3 83 17 0 75 23 2 65 29 6 81 19 0
Trimethoprim 99 0 1 97 0 3 100 0 0 100 0 0 100 0 0 100 0 0
S, susceptible; I, intermediate resistant; R, resistant.
aAll strains were susceptible to ceftazidime, chloramphenicol, ciprofloxacin, cefotaxime, cefepime, florfenicol, gentamicin, kanamycin, levofloxacin, trimethoprim/sulfamethoxazole and
tetracycline.
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TABLE 4 | Antimicrobial MIC distributions for the V. cholerae and V. vulnificus isolates tested.
Antimicrobial
agent
Test range
(mg/L)
Breakpointsa
(mg/L)
MIC (mg/L) distribution
for V. vulnificus (n = 141)
MIC (mg/L) distribution
for V. cholerae (n = 184)
S I R MIC50 MIC90 Range MIC50 MIC90 Range
Ampicillin 0.5–32 ≤8 16 ≥32 1 2 ≤0.5–2 2 8 ≤0.5–>32
Cefotaxime 0.06–4 ≤1 2 ≥4 ≤0.06 ≤0.06 ≤0.06–0.12 ≤0.06 ≤0.06 ≤0.06–0.12
Ceftazidime 0.25–16 ≤4 8 ≥16 ≤0.25 ≤0.25 ≤0.25–0.5 ≤0.25 ≤0.25 ≤0.25–0.5
Chloramphenicol 2–64 ≤8 16 ≥32 ≤2 ≤2 ≤2 ≤2 ≤2 ≤2
Ciprofloxacin 0.008–8 ≤1 2 ≥4 0.015 0.03 ≤0.008–0.06 ≤0.008 ≤0.008 ≤0.008–0.5
Florfenicol 2–64 ≤4 8 ≥16 ≤2 ≤2 ≤2 ≤2 ≤2 ≤2
Gentamicin 0.25–32 ≤4 8 ≥16 2 2 0.5–4 1 2 ≤0.25–4
Kanamycin 4–128 ≤16 32 ≥64 8 16 ≤4–32 ≤4 8 ≤4–16
Nalidixic acid 4–64 ≤16 ≥32 ≤4 ≤4 ≤4–8 ≤4 ≤4 ≤4–>64
Streptomycin 2–128 ≤16 32 ≥64 16 32 4–64 16 32 8–64
Tetracycline 1–64 ≤4 8 ≥16 ≤1 ≤1 ≤1–2 ≤1 ≤1 ≤1
Trimethoprim 0.5–32 ≤8 ≥16 1 1 ≤0.5–4 ≤0.5 1 ≤0.5–>32
S, susceptible; I, intermediate resistant; R, resistant.
aCriteria used for interpretation and corresponding references are given in Supplementary Table S3.
majority of isolates (67%) were susceptible to all antimicrobial
agents tested (with the exception of colistin). Eighteen per cent
of the strains showed intermediate resistance to one or two
antimicrobial agents (mostly to streptomycin) and the remaining
strains (15%) showed full resistance to at least one antimicrobial
agent. None of the V. cholerae isolates showed multidrug-
resistance, defined as resistance to three or more classes of
antimicrobial agents (Chen et al., 2010). Resistance profiles are
shown in Supplementary Table S2, while resistance occurrence is
given in Table 2.
As observed among V. vulnificus, all V. cholerae strains
were susceptible to ciprofloxacin, chloramphenicol, florfenicol,
cefotaxime, sulfamethoxazole-trimethoprim, levofloxacin,
ceftazidime, cefepime, gentamicin, kanamycin, and tetracycline.
Additionally, 98% of the isolates were susceptible to
amoxicillin/clavulanic acid. The most effective clinically relevant
agents in vitro were ciprofloxacin, cefotaxime, ceftazidime, and
tetracycline as they showed MIC90 values identical to the lowest
concentration tested (Table 4).
Similar to the V. vulnificus isolates, a small proportion of V.
cholerae strains showed resistance to streptomycin (2%), while
20% of the strains were intermediate resistant. In contrast to
V. vulnificus, the most frequent antimicrobial resistance found
among all V. cholerae isolates was resistance to ampicillin
(11%). Resistance to nalidixic acid and trimethoprim was rarely
observed in two clinical isolates and in one isolate from
seafood. Non-susceptibility to the carbapenems imipenem and
meropenem was observed in 5 and 3% of the environmental
isolates, respectively.
Clinical strains showed the highest percentage of non-
susceptible strains (44%), followed by environmental strains
(34%) and by strains isolated from retail seafood (23%)
(Table 3). However, statistical analysis revealed that the
observed differences to environmental isolates are not significant
(p > 0.05, χ2). Comparison between the geographical
origin of environmental strains revealed that the percentages
of strains non-susceptible to streptomycin, ampicillin,
amoxicillin/clavulanic acid, meropenem, and imipenem were
higher in the North Sea compared to the Baltic Sea (Table 2).
The higher occurrence of non-susceptible V. cholerae strains in
the North Sea (Table 3) was statistically significant (χ2 = 5.327,
d.f.= 1, p < 0.05).
Analysis of MIC distributions revealed that susceptibilities of
the two Vibrio species were rather similar (Table 4). Differences
were exclusively observed for kanamycin and ciprofloxacin,
where MIC90 values of V. cholerae were two and four times lower
and in case of ampicillin four times higher than those for V.
vulnificus.
Susceptibility to colistin was excluded from any statistical
analysis and tables, since V. vulnificus and V. cholerae possess an
intrinsic resistance to colistin, which is used for selective growth
on cellobiose-polymyxin B-colistin agar (Massad and Oliver,
1987). However, five V. cholerae strains were highly susceptible
to colistin (MICs ≤ 2 mg/L) and would therefore fail to grow on
this selective agar.
Neither class 1 integrons, nor gene determinants encoding
streptomycin resistance (aadA1, aadA2, strA/B) were detected
among non-susceptible V. cholerae isolates. Sequence analysis of
the rpsL gene revealed three silent point mutations C-198-T, A-
251-T, and G-360-A in two streptomycin resistant V. cholerae
isolates (VN-10191, VN-10192) as well as within a susceptible
isolate (VN-4226). In addition, PCR amplifications to detect β-
lactamase genes (blaPSE−1, blaOXA−1−like, blaTEM−1−like) were
negative in all tested V. cholerae isolates.
Examination of Carbapenem
Non-susceptible V. cholerae Isolates
Among the 131 environmental V. cholerae non-O1/non-O139
isolates analyzed, resistance to the carbapenem imipenem (zone
diameter≤ 19) was observed in four strains (VN-2808, VN-2825,
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VN-2923, and VN-2997). These strains additionally showed
resistance to ampicillin, intermediate resistance to amoxicillin-
clavulanic acid, as well as intermediate or full resistance to
meropenem (Table 5). In contrast, they were susceptible to
the third- and fourth-generation cephalosporins ceftazidime,
cefotaxime, and cefepime. Further characterization revealed
resistance to aztreonam and ertapenem, while the strains were
susceptible to temocillin and intermediate resistant to cefoxitin.
The four strains grew on chromID™ CARBA agar, while growth
was inhibited on chromID™ OXA-48 (bioMérieux GmbH,
Nürtingen, Germany), indicating the expression of carbapenem-
hydrolyzing enzymes other than OXA-48 type carbapenemases.
To further investigate the presence of carbapenemases, Blue-
CARBA and Carba NP II tests were conducted on these strains.
Imipenem-hydrolyzing activity was detected in intact cells and
crude cell extracts of each of the four strains. This activity
was inhibited by tazobactam but not by EDTA, suggesting
the presence of Ambler class A carbapenemases rather than
class B metallo-carbapenemases or class D OXA-carbapenemases
(Dortet et al., 2012).
PCRs to identify genes encoding Ambler class A
carbapenemases were performed. However, no products
with expected sizes were observed using primers for detection of
NMC-A, SME 1-3, IMI 1-3, or KPC 1-5. In the case of NMC-A,
SME, and IMI, a general failure of PCR amplification cannot be
excluded as no positive control strains were available.
In addition, the strains were negative for PCR-amplification of
specific genes encoding Ambler class B metallo-carbapenemases
(VIM 1-2, IMP, NDM-1), class D carbapenemase (OXA-48),
and AmpC-β-lactamases (MOX 1-2, CMY 1-11, LAT 1-4, BIL-
1, DHA 1-2, ACC, MIR-1T, ACT-1, FOX 1-5b) as well as of class
1 integrons.
DISCUSSION
Prevalence of Antimicrobial Resistance in
V. vulnificus and V. cholerae
non-O1/non-O139
In this study, V. vulnificus isolates from German coastal waters
as well as of clinical origin were susceptible to quinolones,
fluoroquinolones, phenicols, tetracyclines, folate pathway
inhibitors, aminopenicillins with or without β-lactamase
inhibitors, carbapenems, and third- and fourth-generation
TABLE 5 | β-lactam MIC values and inhibition zone diameters found in the putative carbapenemase-producers and in carbapenem susceptible isolates
selected as negative controls.
Antimicrobial
agent
Strain ID of V. cholerae isolates
Breakpointsd Putative carbapenemase-producers Carbapenem susceptible controls
S I R VN-02997 VN-02825 VN-02923 VN-02808 VN-10145 VN-00301 VN-00161
MIC values
(mg/L)a
Ampicillin ≤8 16 ≥32 >32 >32 >32 >32 2 2 2
Cefepime ≤8 16 ≥32 0.5 0.25 0.5 0.25 0.12 ≤0.06 ≤0.06
Cefoxitin ≤8 16 ≥32 16 16 16 16 4 4 4
Cefotaxime ≤1 2 ≥4 0.12 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
Ceftazidime ≤4 8 ≥16 0.5 0.5 ≤0.25 ≤0.25 ≤0.25 ≤0.25 ≤0.25
Ertapenem ≤0.5 1 ≥2 2 >2 >2 2 0.12 0.03 0.06
Imipenem ≤1 2 ≥4 16 >16 >16 16 1 0.5 1
Temocillin ≤8 - >8 4 4 4 4 4 1 1
Inhibition
zone
diameter
(mm)b
Amoxicillin/
clavulanic acid
≥18 14–17 ≤13 14 13.5 14 15 23 28 18
Aztreonam ≥21 18–20 ≤17 12 15 17 16 NA NA 29
Cefepime ≥25 19–24 ≤18 28 26 28 28 34 40 30
Ceftazidime ≥21 18–20 ≤17 28 26 28 28 NA NA 31
Imipenem ≥23 20–22 ≤19 14 15 16 15 30 36 26
Meropenem ≥23 20–22 ≤19 20 20 20 19 34 36 28
β-lactam resistance phenotypec (AMC)-
AMP-ATM-
ETP-(FOX)-
IPM-(MEM)
(AMC)-
AMP-ATM-
ETP-(FOX)-
IPM-(MEM)
(AMC)-
AMP-ATM-
ETP-(FOX)-
IPM-(MEM)
(AMC)-
AMP-ATM-
ETP-(FOX)-
IPM-MEM
– – –
MIC, minimal inhibitory concentration; S, susceptible; I, intermediate resistant; R, resistant; NA, not assessed; AMC, amoxicillin/clavulanic acid; AMP, ampicillin; ATM, aztreonam; ETP,
ertapenem; FOX, cefoxitin; IPM, imipenem; MEM, meropenem.
aMIC values obtained by broth microdilution.
b Inhibition zone diameter obtained by disk diffusion.
cResults against non-β-lactams are not displayed; intermediate resistance is shown in brackets.
dCriteria used for interpretation with corresponding references are given in Supplementary Table S3.
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cephalosporins. Non-susceptibility was exclusively observed
toward aminoglycosides; predominantly streptomycin and
sporadically kanamycin. Similar observations were made by Han
et al. (2007), who reported total susceptibility with comparable
MIC90 values to chloramphenicol, ampicillin, ceftazidime,
cefotaxime, ciprofloxacin, gentamicin, and tetracycline among
V. vulnificus isolates from oysters of the Louisiana Gulf coast,
USA (Han et al., 2007). In a recent study of V. vulnificus
isolates from the Chesapeake Bay, USA (Shaw et al., 2014),
the highest percentage of resistance was also observed against
streptomycin. However, a large percentage of intermediate
resistant strains to chloramphenicol (78%) and sporadically
non-susceptibility to β-lactams was also reported in that study
(Shaw et al., 2014). Compared to our study, higher percentages
of non-susceptible strains to ampicillin, tetracycline, nalidixic
acid, trimethoprim, and especially to the aminoglycosides
streptomycin and gentamicin were observed in a study of 151 V.
vulnificus isolates from South Carolina, USA, while resistance
to chloramphenicol and meropenem was under one per cent
(Baker-Austin et al., 2009).
Among V. cholerae non-O1/non-O139 isolated from clinical,
environmental, and seafood samples in Germany, no multidrug-
resistance was observed and the majority (67%) of isolates were
susceptible to all antimicrobial agents tested. Full resistance was
most frequently found toward ampicillin (11%) and streptomycin
(2%). In addition, a considerable proportion of isolates showed
intermediate resistance to streptomycin (20%). Resistance to
nalidixic acid and trimethoprim was only sporadically found
in isolates from clinical and seafood samples, respectively.
While numerous studies on antimicrobial resistance of toxigenic
V. cholerae O1, O139 strains have been published, data on
V. cholerae non-O1/non-O139 are less frequent. A recent
study showed similar antimicrobial resistance patterns among
environmental V. cholerae non-O1/non-O139 isolates from the
Chesapeake Bay, USA (Ceccarelli et al., 2015). No multidrug-
resistant isolates were detected and resistance to β-lactams was
found in some isolates. In one large-scale study from India
on antimicrobial susceptibility of V. cholerae non-O1/non-O139
isolates, the highest percentage of resistant strains was also seen
for ampicillin (88%) and streptomycin (85%) though with a
considerably higher frequency (Kumar et al., 2009). In contrast
to our study, Kumar et al. (2009) reported a high prevalence of
multidrug resistance and only a small percentage of strains were
susceptible to all ten antimicrobial agents tested (12%).
Several PCR analyses were performed to reveal the underlying
molecular mechanisms responsible for the observed non-
susceptibility to streptomycin, ampicillin, and imipenem.
Resistance to streptomycin is often mediated by enzymatic
inactivation through adenylation by aminoglycoside (3′′)
adenyltransferases (aadA genes) or through phosphorylation
by aminoglycoside phosphotransferases (strA/strB genes; Shaw
et al., 1993; Tsai et al., 2014). However, none of the Vibrio isolates
was positive for amplification of aadA1, aadA2, or strA/B genes
that are commonly found in Enterobacteriaceae and that have
already been identified in V. cholerae (Hochhut et al., 2001;
Sá et al., 2010; Yu et al., 2012). Ribosomal alterations resulting
from mutations in the rpsL gene encoding ribosomal protein
S12 can be another cause of streptomycin resistance (Shaw
et al., 1993; Tsai et al., 2014). However, amino acid sequences
of ribosomal protein S12 were identical in all investigated
strains, irrespective of the streptomycin resistance phenotype.
Observed single nucleotide polymorphisms within the rpsL
gene of some resistant as well as of some susceptible isolates
were silent mutations. This indicates that other streptomycin
inactivating enzymes or other resistance mechanisms, such
as decreased permeability or other ribosomal alterations (e.g.,
mutations in the rrs gene encoding the 16S ribosomal RNA) may
be responsible for the observed phenotype (Shaw et al., 1993;
Tsai et al., 2014).
Likewise, all β-lactam non-susceptible Vibrio isolates
were negative for amplification of blaPSE−1, blaOXA−1−like,
and blaTEM−1−like genes encoding common β-lactamases in
Enterobacteriaceae and other Gram-negative bacteria. This
suggests that resistance may be encoded by other β-lactamase
genes which are known to show a high diversity in Gram-
negative bacteria. β-lactam resistance may also be mediated
by other mechanisms such as reduced permeability, increased
eﬄux, or target alterations (e.g., reduced affinity or increased
amount of penicillin-binding protein (PBP); Foster, 1983).
Carbapenemase Producing V. cholerae
Antimicrobial susceptibility patterns as well as growth patterns
on different selective media indicated the presence of a
β-lactamase with carbapenem hydrolyzing activity in four
environmental V. cholerae non-O1/non-O139 isolates from the
Baltic Sea and the North Sea. The expression of carbapenemases
was confirmed by positive Blue-CARBA and positive Carba
NP II tests, which specifically detect imipenem hydrolyzing
activity (Dortet et al., 2012; Pires et al., 2013). Inhibition
of carbapenemase activity by tazobactam but not by EDTA
suggested the presence of Ambler class A carbapenemases
rather than class B metallo-carbapenemases or class D OXA-
carbapenemases (Dortet et al., 2012). However, we found no
evidence for the presence of specific genes encoding Ambler class
A carbapenemases.
The four strains showed an exceptional resistance profile:
They were non-susceptible to aminopenicillins, carbapenems,
cefoxitin, and aztreonam and were only slightly inhibited by the
β-lactamase inhibitor clavulanic acid. However, they were fully
susceptible to third- and fourth-generation cephalosporins as
well as to temocillin. The observed resistance to aminopenicillins
coupled with susceptibility to extended spectrum cephalosporins
may indicate the presence of an OXA-type carbapenemase
(Ambler class D) reviewed by Walther-Rasmussen and Høiby
(2006). However, with some exceptions, e.g., OXA-23, these
enzymes are generally not inhibited by tazobactam, as seen for
the four strains in the Carba NP II and Blue-CARBA tests
and generally don’t mediate resistance to aztreonam (Walther-
Rasmussen and Høiby, 2006).
So far, the identity of the enzyme responsible for imipenem
hydrolyzing activity in the four strains remains unclear, as none
of the examined carbapenemase and AmpC-β-lactamase genes
could be detected. It cannot be excluded that in addition to a
carbapenem hydrolyzing enzyme other resistance mechanisms,
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such as reduced affinity of PBPs, porin alterations resulting in
decreased membrane permeability or active eﬄux systems, either
alone or in combination may also contribute to the observed
phenotype (Walther-Rasmussen and Høiby, 2006; Queenan and
Bush, 2007; Nordmann et al., 2012). Carbapenem-resistant V.
cholerae have already been reported in other studies. NDM-1
carbapenemase was detected in a V. cholerae O1 El Tor Ogawa
strain isolated from a 2-year old child (Mandal et al., 2012) as
well as in V. cholerae isolated from seepage water in India (Walsh
et al., 2011). Furthermore, increasing resistance to carbapenems
was recently described among V. cholerae O1 or O139 strains
isolated between 1986 and 2012 in southwest China (Gu et al.,
2014).
CONCLUDING REMARKS
In this study, antimicrobial agents recommended as first choice
agents for the treatment of V. vulnificus and V. cholerae non-
O1/non-O139 infections such as fluoroquinolones, tetracyclines,
and extended spectrum cephalosporins were found to be effective
in vitro against both species. However, the administration
of aminopenicillins, carbapenems, or aminoglycosides for
treatment ofV. cholerae non-O1/non-O139 infections, which has
been reported in few studies (Daniels and Shafaie, 2000; Feghali
and Adib, 2011; Lu et al., 2014) should be considered carefully,
as non-susceptibility was most frequently observed against
ampicillin and streptomycin and sporadically to carbapenems.
For V. vulnificus, non-susceptibility was exclusively observed
to the aminoglycosides streptomycin and kanamycin. However,
gentamicin was effective against both species and could be an
aminoglycoside of choice for the treatment of children and
pregnant woman, as was also suggested by others (Shaw et al.,
2014).
We report the detection of carbapenemase producing V.
cholerae from different locations of the German coast line
(North Sea and Baltic Sea) representing an environmental
reservoir of carbapenem resistance. An entry into the sea
resulting from sanitary pollution or human recreational activities
cannot be excluded, but seems not likely as vibrios are
indigenous bacteria of the marine environment and not intestinal
commensals of humans or terrestrial animals. The strains
displaying carbapenemase activity showed resistance to an
unusual pattern of β-lactams. Therefore, characterization of
the underlying genetic background is necessary to identify the
responsible genes e.g., using whole genome sequencing as the
most promising approach. Further investigations on the mobility
as well as on the location of encoding genes are also needed, since
location on mobile genetic elements would imply a higher risk
for interspecies spread. Carbapenems are last line antimicrobial
agents for treatment of multidrug-resistant Gram-negative
bacteria and are of high therapeutic value (Nordmann et al.,
2012). The occurrence of putative carbapenemase producing
V. cholerae in the North and Baltic Sea is therefore of great
concern and highlights the need for systematic monitoring of
antimicrobial susceptibility in potentially pathogenic Vibrio spp.
in Europe.
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